



Contact:
Suzanne Collier
Marketing Communications
888 TEVA USA

TEVA USA Introduces Zonisamide Capsules

North Wales, Pennsylvania, April 4, 2006 – TEVA Pharmaceuticals USA is pleased to announce the introduction and availability of Zonisamide Capsules. This product is AB rated and bioequivalent to Zonegran®*. Zonisamide Capsules are available in 25 mg, 50 mg and 100 mg strengths, in bottles of 100.

“We are pleased to announce our launch of Zonisamide Capsules,” states John Denman, National Sales Director. “This new product continues our long tradition of providing customers with generic drugs of the highest quality, yet at affordable pricing.”

TEVA Pharmaceuticals USA, located in North Wales, Pennsylvania, is the leader among generic manufacturers for both new and total prescriptions.† The company has an aggressive Research and Development effort and one of the best overall ANDA approval records in the industry.‡

* Zonegran® is a registered trademark of the Dainippon Pharmaceutical Co.

† Data on file, Teva USA.

‡ Please see accompanying prescribing information.